COMMUNIQUÉS West-GlobeNewswire

TRACON Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
08/08/2018
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]
CytomX Therapeutics Announces Second Quarter 2018 Financial Results
08/08/2018
- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) - - Preliminary Proof-of-Concept for Probody™ Platform and [...]
Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
08/08/2018
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs [...]
MyoKardia Reports Second Quarter 2018 Financial Results
08/08/2018
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company [...]
Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments
08/08/2018
Second quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $73.5 million CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical [...]
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results
08/08/2018
REDWOOD CITY, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018. Second Quarter [...]
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
08/08/2018
Net revenue $73.1 million for the second quarter of 2018, 1,952% increase vs second quarter 2017, 15% vs first quarter 2018 Xtampza ER prescriptions grew by 23% in the second quarter of 2018 Cash balance at end of 2018 [...]
Celldex Provides Corporate Update and Reports Second Quarter 2018 Results
08/08/2018
HAMPTON, N.J., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018. The Company will host a conference [...]
Chembio Diagnostics Reports Second Quarter 2018 Financial Results
08/08/2018
MEDFORD, N.Y., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic testing, today reported financial results for the second quarter ended June 30, 2018. [...]
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Corporate Progress
08/08/2018
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes [...]
Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs
08/08/2018
IRVING, Texas, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product development programs and [...]
G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update
08/08/2018
Presenting additional data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer at ESMO 2018 in October Initiated Phase 2a enrollment of lerociclib (G1T38) in ER+, HER2- breast [...]
Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
08/08/2018
Company Focused on Responding to FDA for Third-generation Trial NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens in 4Q2018 Controlled IL-12 Monotherapy, Combination Studies [...]
Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update
08/08/2018
REHOVOT, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing [...]
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates
08/08/2018
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs [...]
Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools
08/08/2018
-- Sarepta expands its presence in gene therapy and broadens its reach with license to up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s gene therapy candidate for Pompe Disease [...]
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results
08/08/2018
-- Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR) Deficiency Obesity -- -- Announced New Topline Clinical Data from [...]
Spring Bank Announces Proposed Public Offering of Common Stock
08/08/2018
HOPKINTON, Mass. and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced that it intends to offer and sell, subject to market conditions, shares of its common [...]
FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
08/08/2018
-- Positive vote for both the skin infections and pneumonia indications -- -- FDA decision expected in early October 2018 -- BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today [...]

Pages